Find Clinical Trials

Inclusion Criteria: * Veterans with self-report of moderate to severe, high impact chronic low back pain (defined as 4/10 in severity via NRS, present 3 months on most days) and associated pain interference (defined as T-score 60 on the PROMIS Pain Interference measure), and current significant depressive symptoms (defined as a score 11 on the Quick Inventory of Depressive Symptoms - Self Report (QIDS-SR). * Medically stable (no hospitalizations in the past month lasting 3 days). * No changes in pain or depression medication regimen in 4 weeks. * No planned surgery, injections, hospitalizations, or other new interventions for back pain (except for physical therapy or exercise) or depression during the next four months (study duration). * Participants must have an adult who can drive them home after the ketamine treatments. Exclusion Criteria: * Inability to speak English due to the narrative intervention being conducted in English. * Inability or unwillingness to provide written informed consent (e.g. current delirium). * Current psychotic symptoms, or history of schizophrenia, schizoaffective disorder, and other psychotic disorder. * Currently participating in another clinical trial for pain or depression. * Current uncontrolled hypertension (defined as systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg). * Known elevated intracranial pressure, cerebral arterial aneurysm, or elevated intraocular pressure. * History of cirrhosis or unstable cardiac condition (e.g., decompensated congestive heart failure). * Any of the following lab values \>2x upper limit of normal: alanine transaminase (ALT), aspartate transferase (AST), direct bilirubin, alkaline phosphatase, creatinine; thyroid stimulating hormone (TSH) \<2x lower limit of normal or \>2x upper limit of normal. * Positive urine pregnancy test or lack of birth control method in Veterans of childbearing potential. * Known hypersensitivity to any excipient in the ketamine injection formulation. * Previously experienced serious adverse effects with ketamine. * On day of ketamine infusions, a urine drug screen positive for non-prescribed substances(s) (except cannabis) will exclude a participant from receiving ketamine * Current or previous abuse of ketamine.

Inclusion Criteria: 1. Age ≥ 18 years. 2. A diagnosis of an anxiety disorder (generalized anxiety disorder, social anxiety disorder, or panic disorder with or without agoraphobia) and/or mild to moderate major depressive disorder (MDD) according to DSM-5 (American Psychiatric Association, 2022). 3. Danish language proficiency. 4. Ability and willingness to give informed consent. 5. No or stable antidepressant/antianxiety medication (i.e., same dosage for ≥ 8 weeks). 6. Access to either a smartphone, tablet, or computer with video camera. Exclusion Criteria: 1. Severe depression deemed to require more intense psychotherapy or medication. 2. Persistent depressive disorder (i.e., depressive symptoms have persisted for 2 years or more). 3. Non-stabilized medication (see above). 4. Currently receiving other psychotherapy or counseling. 5. Not capable of participating online. 6. Lack of Danish proficiency. 7. A history of bipolar disorder. 8. Current or past psychosis. 9. Substance abuse or dependence judged to require treatment. 10. Suicide risk requiring immediate hospitalization.

Inclusion Criteria: 1. The patient must be diagnosed with non-psychotic unipolar Major Depressive Disorder. 2. The patient must be in a major depressive episode for ≥12 months or have had at least 3 lifetime depressive episodes. 3. The patient has tried and failed a minimum of four different types of antidepressant treatments as measured by a tool designed for this purpose. 4. Depression medication and treatment regimen must be stable for a minimum of 4 weeks before the first baseline visit Exclusion Criteria: 1. Pregnant or those who plan to become pregnant during study 2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol. 3. Current or lifetime history of psychotic features in any Major Depressive Episode. 4. Has an intracranial Central Nervous System disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication. 5. Significant acute suicide risk. 6. Diagnosis of Substance Use Disorder or Alcohol Use Disorder without sustained remission (12 months or longer). 7. Current and ongoing use of neurostimulation treatment that may interfere with DBS therapy/system. 8. Treatment with another investigational device or investigational drugs.

Inclusion Criteria: * Has type 2 diabetes * Has a score above 2 on the T2D Distress Assessment Scale Exclusion Criteria: * Does not have type 2 diabetes * Has a score above 2 on the T2D Distress Assessment Scale * Cannot safely exercise * Cannot complete the requested tasks

Inclusion Criteria The participant must meet all of the inclusion criteria to eligible for this clinical trial: 1. Must be deemed to have capacity to provide informed consent; 2. Must be an outpatient 3. Have a DSM 5 diagnosis of bipolar disorder (type I or II), current episode depressed confirmed by Mini-International Neuropsychiatric Interview version 7.0.2 (MINI); 4. Age 18-65; 5. failure to achieve a clinical response to ≥1 adequate treatment trial for bipolar depression based on the Antidepressant Treatment History Form - Short Form (ATHF-SF) OR unable to tolerate at least 2 separate inadequate treatment trials for bipolar depression;43 6. moderately severe depression with a score ≥ 15 on the PHQ-9;44 7. not currently experiencing a mixed or manic episode (YMRS ≤10); 8. no increase or initiation of psychotropic medication with intention of treating depressive symptoms in the 4 weeks prior to screening. This excludes targeted treatment of insomnia with trazodone, melatonin, low-dose doxepin \[3-6mg\], low-dose benzodiazepines \[≤2mg lorazepam daily equivalent\], non-benzodiazepine benzodiazepine receptor agonists, or orexin antagonists; 9. able to adhere to the treatment schedule; 10. pass the TMS adult safety screening questionnaire.45 Exclusion Criteria An individual who meets any of the following criteria will be excluded from participation in this clinical trial: 1. have a history of MINI diagnosis of a substance use disorder (other than nicotine and/or caffeine) within the last 3 months; 2. have a concomitant major unstable medical illness; 3. have active suicidal intent (assessed during HRSD-17 Item 3 and SSRS as imminent intent to act on specific plan, confirmed by psychiatric staff); 4. are pregnant or intend to get pregnant during the study; 5. have a lifetime MINI diagnosis of schizophrenia or schizoaffective disorder; 6. have psychotic symptoms within the current episode; 7. have a MINI anxiety disorder, trauma-related disorder, obsessive compulsive disorder, or personality disorder assessed by a study investigator to be primary and/or causing greater impairment than BD-DE; 8. failure of an adequate acute course of ECT as defined by ATHF-SF during the current episode; 9. have received any rTMS before due to potential to compromise blinding of treatment allocation; 10. have any clinically significant neurological disorder (e.g., recent major cerebrovascular accident), or any history of seizure except those therapeutically induced by ECT or with clear precipitant (e.g., febrile seizure of childhood, alcohol withdrawal, etc.); 11. have any intracranial implant (e.g., aneurysm clips, shunts, stimulators,) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed; 12. are participating in psychotherapy for less than 3 months. Patients will be permitted if they have been in stable treatment for at least 3 months prior to study entry, with no anticipated change in the frequency of therapeutic sessions, or focus of therapeutic sessions over the duration of the study; 13. are currently taking lorazepam \>2 mg daily (or equivalent) due to the potential to limit rTMS efficacy; 14. are currently taking any dose of an anticonvulsant due to the potential to limit rTMS efficacy. If anticonvulsants have been discontinued prior to screening, at least 5 half-lives have elapsed until screening to allow sufficient drug clearance; 15. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).

Inclusion Criteria: 1. Adult (≥ 18 years at the time of informed consent signature) male or female patient 2. Patient with confirmed de novo or pre-treated metastatic solid tumors (multiple previous treatment lines in metastatic setting are allowed). 2.1. Patients with documented hormone receptor positive/HER2 negative, triple-negative or HER2 positive mBC that could become eligible for commercially available HER2 targeted monotherapy (i.e. through confirmation of HER2 IHC non-0 status assessed during the course of the study) or 2.2 Other metastatic solid tumors, not necessarily eligible for commercially available HER2 targeted monotherapy . 3. Patient presenting with at least one target biopsiable, FDG positive , non-liver metastatic lesion of ≥15 mm defined on ceCT (as part of screening 18F-FDG PET/ceCT assessment). 4. Patient willing to undergo at least one tumor biopsy. 5. Male patients able to father children and female patients of childbearing potential agree to use effective methods of contraception during the diagnostic and SOCa treatment follow-up study phases. 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 7. Ability and willingness of the research participant to provide written informed consent. Exclusion Criteria: 1. Primary (non-metastatic) solid tumor cancer. 2. Patient not willing to undergo at least one tumor biopsy. Note: A recent biopsy and accompanied locally assessed IHC/ISH analyses, completed before screening, will not be accepted for study purposes. 3. 18F-FDG PET/ceCT completed before screening and patient not willing to repeat this assessment. 4. Metastatic setting 18F-FDG PET/ceCT indicating that the identified tumor lesions cannot be biopsied due their location and/or tissue type and/or an increased risk for serious comorbidities. 5. Brain and liver metastases are the sole sites of metastatic disease. 6. Life expectancy lower than 3 months. 7. Pregnancy or breastfeeding. 8. Inadequate organ function, suggested by clinically relevant abnormal laboratory results: 1. Significantly impaired renal function defined as estimated Glomerular Filtration Rate (GFR) \<30 ml/min/1.73m2. 2. Absolute neutrophil count \<1,500 cells/mm3. 3. Total bilirubin \~1.5 x Upper Limit of Normal (ULN) (unless the patient has documented Gilbert's syndrome). 4. Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or Alanine aminotransferase (ALT)/ serum glutamic pyruvic transaminase (SGPT) \>5.0 x ULN. 9. Patients with a known hypersensitivity to any of the investigational medicinal product (IMP) components or packaging. 10. Patients with increased risks of bleeding or other complications from biopsies (e.g. patients under anticoagulation therapy for whom temporary discontinuation of this therapy cannot be safely performed). 11. Patients with a known hypersensitivity or contraindication for iodinated contrast media (iCM) which cannot be controlled by taking prophylactic measures (e.g. temporary treatment interruption or introduction of adequate pre-medication). 12. Patients who cannot undergo PET/CT scanning (including but not limited to body size and claustrophobia). 13. Any condition that in the opinion of the investigator may significantly interfere with study compliance (including but not limited to psychological or psychiatric, social or geographical condition potentially hampering compliance with the study requirements).

The project is based on combined analyses of nine cohorts from Denmark and Sweden: The inclusion criteria for the Danish Diet Cancer and Health (DCH) cohort were age between 50 and 64 y, residing in the greater Copenhagen or Aarhus area and without a cancer diagnosis. From 1993 to 1997, 160,725 Danes were invited to participate of whom 57,053 participants accepted the invitation and were enrolled in the study. All participants completed detailed questionnaires at enrolment and trained staff members measured height, weight, and waist circumference. The Danish Nurse Cohort (DNC) was initiated by sending questionnaires to the members of the Danish Nurse Organization in 1993 and 1999. Among 33,704 eligible female nurses aged 44-93 years who either worked or were retired in 1993 or 1999, 28,731 participants (85·2%) were included in the DNC. Upon enrolment, participants answered a comprehensive questionnaire on body mass index (BMI), lifestyle factors (smoking, alcohol consumption, physical activity, and dietary habits), self-reported diseases and reproductive health, and working conditions. The Stockholm Diabetes Preventive Programme (SDPP) is a prospective cohort aimed at investigating the aetiology of type 2 diabetes and cardiometabolic risk factors. The cohort comprises 34 486 men and women aged 35-56 years who lived in five municipalities in Stockholm County 1992-1998. A sub-sample of 7,949 individuals were invited to a clinical examination at baseline and were followed up 2002-2006 and 2014-2017. During the clinical examinations, blood pressure was measured along with anthropometric measurements, blood samples were collected, oral glucose tolerance tests were administered, and participants answered extensive questionnaires concerning lifestyle factors, health status, socioeconomic characteristics, and psychosocial conditions. The SIXTY cohort is based on a random sample of every third man and woman living in Stockholm County, who were born in 1937 and 1938. A total of 4,232 subjects were recruited 1997-1999 to investigate risk factors for cardiovascular disease. People were 59- 61 years at enrolment. Measurements of anthropometric indices and blood pressure were made at recruitment and fasting blood samples were collected. In addition, a comprehensive questionnaire was completed, including information on socioeconomic, medical and lifestyle factors. The Screening Across the Lifespan Twin Study (SALT) included a total of about 45 000 twins born 1958 and earlier from the Swedish Twin Registry who were interviewed 1998-2002. Those 7,043 who resided in Stockholm County at recruitment are included in the present project. People were 42-97 years at enrolment. The interview collected data on zygosity, diseases, use of medication, occupation, education and lifestyle habits. In a subgroup of around 2,500 subjects, a clinical examination was made, including blood sampling and anthropometrics as well as blood pressure measurements The Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) was established 2001-2004 and included 3,363 residents aged 60-104 years in Kungsholmen, Stockholm. The aim was to investigate the ageing process and identify possible preventive strategies to improve health and care in elderly adults. Information was collected through social interviews and clinical examinations, including assessment of physical and cognitive functioning. Follow-up investigations are performed at intervals of three to six years depending on age The Malmö Diet and Cancer (MDC) study is a population based prospective cohort study. People were enrolled into the cohort between 1991 and 1996, and eligible participants were men born between 1923 and 1945 and women born between 1923 and 1950, living in the city of Malmö. Swedish reading and writing skills were required. People were 44-73 years at enrolment. The data collection was done both using questionnaires and interviews, including data on dietary habits, socio-economics, medical history and lifestyle factors. The total number of study subjects was 28,098. The Swedish Mammography Cohort is a population-based prospective cohort study established 1987-90 when all 90,303 women living in Uppsala and Västmanland counties, born 1914-48, were invited to a mammography screening and to respond to a questionnaire (74% response rate). In 1997, the 56,030 participants who were still living in the study area were invited to respond to a second extended questionnaire, (response rate 70 %). In the present project, we included the women from Uppsala County taking part in the 1997 investigation (n= 20,407). The Danish National Health Survey (DNHS) included 177 639 persons aged 16 years and older randomly selected across Denmark who answered a questionnaire in 2010 or 2013.40 Information on age, sex, education and labor market affiliation was obtained from national registers. The questionnaire focused on sex, age, cohabiting status, education, occupation, smoking, alcohol consumption, diet, physical activity and anthropometric data For all cohorts exclusion criteria included illness and insufficient knowledge of Danish or Swedish, making it difficult to answer questionnaires and/or participate in clinical investigattions.

Inclusion criteria (Breast Cancer Group) * Age 18-75 years of age * Diagnosis of breast cancer requiring chemotherapy * Recent (within 6 months) completion of chemotherapy * Willing to attend 3 virtual-based exercise sessions per week * Able to take oral medications * Participant is willing and able to provide consent to participating in the study * Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation. Exclusion criteria (Breast Cancer Group) * Physical indications where performing exercise may be limited and/or contraindicated * Poorly controlled hypertension (blood pressure \> 160/95mmHg) * Current tobacco use (within 6 months) * Anabolic steroids use * Pitting edema greater than 2+ * Currently undergoing chemotherapy treatment for cancer * History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation) * Pregnant or plan to become pregnant during the study * Recent (within one month) or anticipated treatment with corticosteroids (except for short term use during the time of chemotherapy), or other appetite stimulants * Serum creatinine \> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation * Currently taking creatine supplements * Lack of availability to a smartphone and/or internet Inclusion Criteria (Healthy Age-matched Control Group) * Age 18-75 years of age * Have never been diagnosed with cancer * Willing to provide consent to participate in this study Exclusion Criteria (Healthy Age-matched Control Group) * Physical indications where performing exercise may be limited and/or contraindicated * Poorly controlled hypertension (blood pressure \> 160/95mmHg) * Current tobacco use (within 6 months) * Anabolic steroids use * Pitting edema greater than 2+ * History of cancer diagnosis * History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation) * Pregnant or currently taking prescribed medication to prepare for pregnancy (i.e. hormonal therapy for IVF) * Recent (within one month) treatment with corticosteroids * Recent (within one month) use of appetite stimulants or appetite suppressants * Serum creatinine \> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation * Diagnosed Bipolar Disorder or MDQ score indicative of bipolar disorder or Neurological disorders * Uncontrolled diabetes (A1c of 6.5% or higher) * Currently taking creatine supplements * Lack of availability to a smartphone and/or internet

Inclusion Criteria: * Diagnosis of major depressive episode (MDE, in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder. * At least one failed antidepressant medication trial at level 3 in the Antidepressant Treatment History Form: Short Form (ATHF-SF) classification. * Montgomery-Åsberg Depression Rating Scale (MADRS) Score \>19 (moderate - severe depression). * No increase or initiation of new antidepressant therapy in the four weeks prior to screening. * Demonstrated capacity to give informed consent. Exclusion Criteria: * Inability to provide informed consent. * Medically unstable patients. * Concomitant neurological disorder or a history of a seizure disorder. * Exhibiting current suicidal behavior rating on the Columbia Suicide Severity Rating Scale (C-SSRS) * Patients who are pregnant or breastfeeding. * Any psychotic disorder or current active psychotic symptoms. * Patients who have intracranial implants, other medical device or condition deemed unsafe for TMS. * Contraindication to MRI scanning.

Inclusion Criteria: 1. Age 40-80. 2. For women of reproductive potential, a negative pregnancy test at screening and scanning 3. For PD patients, clinical diagnosis of PD, able to consent and tolerate PET procedures 4. For PD depression patients - at least moderate symptom severity as determined by at least 15 on the MADRS, which has shown maximum discrimination between depressed and non-depressed PD patients. 5. For dPD patients undergoing ketamine, abstinence from drugs of abuse, other than alcohol, cannabis, nicotine and caffeine for the duration of the study. Patients with substance use disorders as defined by the DSM-5 will be excluded. Exclusion Criteria: 1. Dementia (Montreal Cognitive Assessment (MoCA) score \<21) 2. A significant primary DSM-5 psychiatric disorder except for MDD 3. A history of or current significant medical (e.g. cardiovascular, renal), or neurological (e.g. cerebrovascular, seizure, traumatic brain injury) illness other than PD that is unstable and significantly increase their risk and/or might affect the study objectives, as determined by study physicians. 4. Prior radiation exposure for research purposes within such that participation in this study would place them over FDA limits for annual radiation exposure 5. Medications affecting SV2A availability (e.g. levetiracetam) 6. For dPD patients receiving ketamine, uncontrolled hypertension, defined as average blood pressure greater than or equal to 140 mmHg or an average diastolic blood pressure greater than or equal to 90 mmHg among those patients who have hypertension. 7. Contraindications to MRI. 8. For patients undergoing arterial sampling for the PET scan: Iodine allergy, bleeding disorder and/or use of blood thinning medication 9. Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.

Inclusion Criteria: * Diagnosis of Bipolar Disorder type I and II according to DSM V * Presence of depressive symptoms (MADRS\>12) * Not undergoing psychotherapy * Availability to attend in-person group therapy sessions * Signing consent form Exclusion Criteria: * Organic mental disorder * Presence of manic or hypomanic symptoms (YMRS\>12) * Currently undergoing psychotherapy (not able to pause during the study) * Major medication change in last 30 days

Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analysis. If a patient declines to participate in any voluntary exploratory research of the study, there will be no loss of benefit to the patient and she will not be excluded from other aspects of the study 2. Women aged at least 18 years 3. The patient has a biopsy-confirmed diagnosis of recurrent, unresectable, locally advanced, or metastatic AR+ TNBC 1. AR+ assessed locally and defined as ≥1% of cells staining on IHC of last recurrent/metastatic breast cancer specimen 2. Local biopsy confirmation of last recurrent/metastatic site with positive IHC for ER and/or PR in ≤10% of cells and negative for HER2 per ASCO/CAP-guidelines 3. Prior invasive (metastatic) breast cancer with positive IHC for ER and/or PR in \>10% of cells is allowed, provided the last biopsy of recurrent/metastatic disease has positive IHC for ER and/or PR in ≤10% of cells 4. Prior invasive (metastatic) HER2-positive breast cancer per ASCO/CAP-guidelines is not allowed 5. The patient has measurable disease per RECIST 1.1 or evaluable bone-only disease with lytic or mixed component that is progressive as evidenced on pre-treatment baseline imaging 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks 5. The patient must have had prior treatment with at least 1 prior cytostatic regimen in advanced setting setting unless treatment with a cytostatic regimen is contraindicated as judged by Investigator. There is no upper limit for prior treatment lines in advanced setting. * Patients with known germline BRCA1/2 pathogenic variants should have received previous treatment with PARP inhibitors in the early/locally advanced or metastatic setting, unless contraindicated. * Prior treatment with palbociclib or ribociclib is allowed, provided at least 6 months have elapsed between last administration and start of study treatment 6. Patients must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of prior anticancer treatment except for residual Grade 2 alopecia, anemia or peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and first dose of study drug (provided the patient did not receive radiotherapy). 7. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization. 8. In females of child-bearing potential, a negative serum or urine pregnancy test within 7 days prior to starting treatment is required. Women of child-bearing potential must agree to use a highly effective method of contraception prior to study entry, for the duration of study participation (in addition to the LHRH-agonist), and for 3 weeks following completion of abemaciclib and for 130 days following completion of bicalutamide. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Exclusion Criteria: 1. Treatment with any of the following: a. Any experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomization. b) Currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study. c. Any other chemotherapy, immunotherapy or anticancer agents within 21 days of the first dose of study treatment d. Treatment with palbociclib or ribociclib within 6 months of the first dose of study treatment e. Any prior exposure to abemaciclib f. Any prior exposure to anti-androgen therapy (bicalutamide, abiraterone, and/or enzalutamide) 2. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment 3. Spinal cord compression, leptomeningeal carcinomatosis, or brain metastases - unless asymptomatic, treated, stable at baseline imaging and not requiring corticosteroids \>10 mg prednisolone daily (or equivalent) for at least 2 weeks prior to start of study treatment 4. Concurrent use of endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane, oral contraceptive pills) 5. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 6. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required. 7. Any of the following cardiac criteria: 1. Mean resting corrected QT interval (QTc) \> 470 msec obtained from 3 consecutive electrocardiograms (ECGs) 2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block) 3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval 4. Personal history of syncope of cardiovascular etiology, ventricular arrhythmia (of pathologic origin including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. 5. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade 2 or greater 6. Uncontrolled hypotension - Systolic BP \<90mmHg and/or diastolic BP \<50mmHg 7. Known left ventricular ejection fraction (LVEF) below lower limit of normal for site 8. Prior history of DVT/PE or embolic stroke, unless currently on therapeutic anticoagulation 9. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: 1. Absolute neutrophil count \< 1.5 x 109/L 2. Platelet count \< 100 x 109/L 3. Hemoglobin \< 8 g/dL (Patients may receive transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.) 4. Alanine aminotransferase \> 3 times the upper limit of normal (ULN) 5. Aspartate aminotransferase \> 3 times ULN 6. Total bilirubin \> 1.5 times ULN (patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted) 7. Creatinine \>1.5 times ULN concurrent with creatinine clearance \< 50 ml/min (measured or calculated per local institutional practice); confirmation of creatinine clearance is only required when creatinine is \> 1.5 times ULN 8. Known proteinuria 3+ on dipstick analysis or \>500mg/24 hours 9. Sodium or potassium outside normal reference range

Inclusion Criteria: * Have one of the following solid tumor cancers: * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC) * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC Exclusion Criteria: * Individual with known or suspected uncontrolled central nervous system (CNS) metastases * Individual with history of carcinomatous meningitis * Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection * Individual with evidence of corneal keratopathy or history of corneal transplant * Any serious unresolved toxicities from prior therapy * Significant cardiovascular disease * Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms) * History of pneumonitis/interstitial lung disease * Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

Inclusion Criteria: * All adults with uncontrolled HTN who receive care through iCHF membership and are able to provide informed consent. Exclusion Criteria: * Adults with controlled HTN or those without a diagnosis of HTN * Unable or unwilling to provide informed consent

Inclusion Criteria: * severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion * Hamilton Depression Rating Scale between between 20 and 35 points at inclusion * The score in the Athens Insomnia Scale eight or more * The score of three or more points in items 4 and 21 of the Beck Depressions Inventory 2 * Complaining about problems with memory and concentration timely related with the onset of depression Exclusion Criteria: * Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy * Psychotic symptoms at the time of inclusion * Suicidal ideations and/or attempts within three months prior to inclusion

Inclusion Criteria: * Between 22w 0/7d and 31w 6/7d gestation at birth * Diagnosed with echocardiographic pulmonary hypertension (1) \>20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index \>1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg * Receiving supplemental oxygen * Have mature retinas Exclusion Criteria: * Major congenital anomalies

Inclusion Criteria: * Women who were medically diagnosed with preeclampsia or a related hypertensive disorder of pregnancy (HDP) such as eclampsia or HELLP syndrome. * Female or Male relatives of affected women * Women who have never had preeclampsia or hypertensive disorders of pregnancy, but who would like to serve as "controls" in research studies of preeclampsia. * An authorized representative may complete the questionnaire and provide consent for a woman who had preeclampsia, but has died or is disabled as a result. Exclusion Criteria: * Those unable to provide consent * Prisoners * Individuals unable to speak English

Inclusion Criteria: * severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion * Diagnosis of major depression (F33.1 or F33.2) or bipolar disorder (F31.3 or F31.4). * The score of the Athens Insomnia Scale five or more * Unchanged antidepressive pharmacotherapy at least one month prior to inclusion Exclusion Criteria: * Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy * Psychotic symptoms at the time of inclusion * Suicidal ideations and/or attempts within three months prior to inclusion

Inclusion Criteria: General criteria (for all cohorts): 1. Women ≥ 18 years old. 2. Invasive breast cancer treated by conservative or radical surgery. 3. Conservative breast cancer surgery or radical mastectomy. 4. Indication of breast irradiation. 5. Extension evaluation of disease will be proven negative (M0). 6. Negative pregnancy test (blood or urine at the choice of investigator), to be carried out within 7 days of registration, for women of childbearing age only. 7. Effective contraception for women of childbearing age 8. Must be geographically accessible for follow-up. 9. Written and dated informed consent. 10. Affiliated to the French national social security system. Cohort A and B: \- Low risk of recurrence (all of the criteria) • pT1-T2 * SBR (Scarff Bloom et Richardson grade) grade ≤ 2 (low grade) * ER+ and / or PR+ (hormone-receptor positive) * cN0/pN- * HER 2 - * Ki67 ≤10% pN- with T3-4 and grade 3 and internal tumor will be considered at high risk of recurrence and will be proposed node irradiation (and will be switched to COHORT C or D). Cohort C and D: \- High risk of recurrence (pN+ and at least one of all) adapted from the UK PREDICT • ER- and PR- • HER2 amplified • pT3-4 • SBR grade ≥ 3 * KI67 \> 10% Cohort A and C: * Low risk of breast toxicities identified by the NovaGray RILA Breast® test Cohort B and D: \- High risk of breast toxicities identified by the NovaGray RILA Breast® test Exclusion Criteria: * 1\. Patients with distant metastases. 2\. Patients with breast DCIS (ductal carcinoma in situ) 3. Concomitant bilateral breast cancer 4. Previous breast radiotherapy 5. Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years. 6\. Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up. 7\. Patients known to be HIV positive (no specific tests are required to determine the eligibility). 8\. Patients known as hypersensitive to radiation 9. Patients treated with systemic investigational drugs during the present study (Observational cohorts are accepted if the collection of data does not interfere with the current trial) 10. Pregnant or breast-feeding women 11. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study 12. Person deprived of their liberty or under protective custody or guardianship

Inclusion Criteria: * are aged between 18 and 70; * have a MDD diagnosis, single or recurrent episode, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition criteria and confirmed by means of the Mini-International Neuropsychiatric Interview (MINI); * have a score of at least 18 on the 17-item Hamilton Rating Scale for Depression (HDRS17) in their current episode; * have failed to have a clinically significant response to two or more standard antidepressant treatments during their current episode; * have received stable psychopharmacological treatment within 4 weeks prior to screening; and * have normal thyroid function, Complete Blood Count, electrolytes, and liver enzyme levels based on pre-study blood work. Exclusion Criteria: * have a history of substance abuse or dependence in the past 3 months; * have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump; * show active suicidal intent (MADRS item 10 score \>4); * are pregnant; * have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms; * have a metal implant or any other common MRI and TMS exclusion criteria; * take antiepileptic drugs or benzodiazepines corresponding to a dose of \>1 mg lorazepam per day; * have had initiation or dose change of any psychotropic medication in the 4 weeks prior to screening or * have undergone TMS in the past.